Search

everythinglearnresearchcommunity

for

Search:↓

The Androgen Receptor could be a target for treating diseases like cancer, but more research is needed to confirm the effectiveness of potential treatments.

Case-only trees and random forests improve predictions of treatment effects in clinical trials.

5-alpha reductase inhibitors, like finasteride and dutasteride, are used for prostate issues, hair loss, and excessive hair growth, may help with COVID-19, but can cause sexual and mental health side effects, and their use in preventing prostate cancer needs more examination.

Preventing cancer involves lifestyle changes, vaccinations, early screening, and understanding cancer's molecular basis.

Using finasteride or dutasteride does not increase the risk of male breast cancer.

The medications 5α-reductase inhibitors and spironolactone are generally safe for breast cancer patients on endocrine therapies and do not significantly increase breast cancer risk.

The PW91 method is best for calculating the basic physical and chemical properties of Finasteride, a drug used for prostate issues and hair loss.

Different drugs for prostate-related urinary symptoms work but have various side effects, and treatment should be tailored to the individual.

New treatments for enlarged prostate are being developed to be more effective and have fewer side effects.

Long-term medication for enlarged prostate might not clearly affect the timing or outcomes of later surgery.

Medications have become the main treatment for enlarged prostate symptoms, replacing surgery and watchful waiting.

5α-reductase inhibitors increase the risk of sexual dysfunction, especially in men with enlarged prostate.

Antiandrogens and androgen inhibitors like spironolactone, finasteride, and dutasteride can treat hair loss and skin conditions, but they have risks and side effects, including potential harm to pregnant women and risks of cancer and heart issues. Herbal remedies also have antiandrogenic effects but lack safety validation.

Modern hair transplants use small grafts for a natural look and drugs to prevent further loss, with high patient satisfaction.

Finasteride and dutasteride effectively treat hair loss in men and women, but may cause side effects like low libido and depression.

5-alpha reductase inhibitors may cause sexual side effects, breast complications, and other health risks in men with hair loss.

5α-reductase inhibitors and alpha-1 adrenergic antagonists together effectively treat benign prostatic hyperplasia, with long-term benefits.

Platelet-rich plasma injections significantly improve hair density and thickness in both male and female pattern hair loss, especially in early stages.

Some treatments work for common baldness, but there's less evidence for other hair loss types, and more research is needed.

Most YouTube hair loss treatment videos are popular but often biased and lack reliable sources.

New chemical compounds were made that effectively block an enzyme linked to prostate growth.

Dutasteride, usually used for prostate issues and hair loss, could potentially treat Amyotrophic Lateral Sclerosis (ALS) due to its neuroprotective, antioxidant, and anti-inflammatory properties, but more testing is needed.

Androgenetic alopecia is linked to heart disease, metabolic issues, and mental health problems.

Androgens like testosterone are important hormones for both men and women, made differently in each sex and affecting the body by regulating genes and quick interactions with cell components.

5-alpha reductase inhibitors slightly increase the risk of sexual and mood side effects, and breast growth in men.

Effective treatments for male pattern baldness include oral finasteride and topical minoxidil, while topical minoxidil is best for female pattern baldness.

S5αR inhibitors might help treat schizophrenia and other mental disorders but need more research.

New alopecia treatments aim for better results and fewer side effects.

Topical tofacitinib may grow hair better than minoxidil by increasing VEGF and reducing inflammation.